Posted by Michael Wonder on 25 Apr 2020
CSL's blood payments in US under the microscope
25 April 2020 - CSL has been forced to defend the way it runs its blood plasma collection business in the US amid concerns the company will face increased scrutiny over how it handles the health and welfare of blood donors.
Wealth manager Australian Ethical, which has $3.8 billion under management, is seeking clarity from the ASX-listed biotech giant on how it will manage the level and frequency of donation payments, at a time when unemployment is ramping up in the US.
The head of ethics at Australian Ethical, Stuart Palmer, said while paying for plasma wasn't in itself unethical, there were concerns that some people may suffer harm from making frequent donations in order to earn money.
